Drug abuse among women is a major societal health problem that has been under-investigated until recently (http://www.nida.nih.gov). Current advances show statistically significant differences between males and females in all phases of drug exposure (acquisition, steady-state maintenance, escalation, dysregulation, withdrawal, relapse, and treatment). Clinical evidence demonstrates that females are more susceptible to relapse compared to males and that this relapse is accompanied by a negative emotional state, notably anxiety. Physiological fluctuations (e.g. menstrual cycle), during drug exposure and following drug abstinence, may contribute to increased female sensitivity to the anxiogenic effects of cocaine. In female rats, gonadal hormones modulate dopamine activity in the nucleus accumbens (NAcb) providing support for sex differences in cocaine’s mechanisms of action. The δ-opioid receptor (DOR) undergoes desensitization following chronic cocaine administration in male rats through a D1R dependent mechanism. This desensitization may mediate anxiogenic responses induced by chronic cocaine administration in females. The guiding hypothesis is that female hormones, via actions on dopamine and opioid systems, may contribute to the increase in anxiety exhibited during cocaine withdrawal.